PURPOSE: Angiogenesis inhibition has emerged as a potentially promising treatment strategy for neuroendocrine tumors. 2-Methoxyestradiol (2ME2; Panzem(®)) is a natural derivative of estradiol with demonstrated anti-angiogenic activity in animal models. We performed a prospective, phase II study of 2ME2, administered in combination with bevacizumab, in patients with advanced carcinoid tumors. METHODS: Thirty-one patients with advanced carcinoid tumors were treated with 2ME2, administered orally at a dose of 1,000 mg four times daily. Patients also received bevacizumab 5 mg/kg intravenously every 2 weeks. Patients were observed for evidence of toxicity, tumor response, and survival. RESULTS: The combination of 2ME2 and bevacizumab was relatively easily tolerated and was associated with anticipated toxicities for these two agents. No confirmed radiologic responses (by RECIST) were observed. However, 68% of the radiologically evaluable patients experienced at least some degree of tumor reduction, and the median progression-free survival (PFS) time was 11.3 months. CONCLUSION: 2ME2 and bevacizumab can be safely administered to patients with advanced carcinoid tumors. While major tumor regression was not observed with this regimen, the encouraging median progression-free survival time suggests that this regimen has some degree of antitumor activity and supports the further investigation of angiogenesis inhibitors in this disease.
PURPOSE: Angiogenesis inhibition has emerged as a potentially promising treatment strategy for neuroendocrine tumors. 2-Methoxyestradiol (2ME2; Panzem(®)) is a natural derivative of estradiol with demonstrated anti-angiogenic activity in animal models. We performed a prospective, phase II study of 2ME2, administered in combination with bevacizumab, in patients with advanced carcinoid tumors. METHODS: Thirty-one patients with advanced carcinoid tumors were treated with 2ME2, administered orally at a dose of 1,000 mg four times daily. Patients also received bevacizumab 5 mg/kg intravenously every 2 weeks. Patients were observed for evidence of toxicity, tumor response, and survival. RESULTS: The combination of 2ME2 and bevacizumab was relatively easily tolerated and was associated with anticipated toxicities for these two agents. No confirmed radiologic responses (by RECIST) were observed. However, 68% of the radiologically evaluable patients experienced at least some degree of tumor reduction, and the median progression-free survival (PFS) time was 11.3 months. CONCLUSION:2ME2 and bevacizumab can be safely administered to patients with advanced carcinoid tumors. While major tumor regression was not observed with this regimen, the encouraging median progression-free survival time suggests that this regimen has some degree of antitumor activity and supports the further investigation of angiogenesis inhibitors in this disease.
Authors: Matthew H Kulke; Emily K Bergsland; David P Ryan; Peter C Enzinger; Thomas J Lynch; Andrew X Zhu; Jeffrey A Meyerhardt; John V Heymach; William E Fogler; Carolyn Sidor; Ann Michelini; Kate Kinsella; Alan P Venook; Charles S Fuchs Journal: J Clin Oncol Date: 2006-08-01 Impact factor: 44.544
Authors: B Terris; J Y Scoazec; L Rubbia; L Bregeaud; M S Pepper; P Ruszniewski; J Belghiti; J Fléjou; C Degott Journal: Histopathology Date: 1998-02 Impact factor: 5.087
Authors: Christopher Sweeney; Glenn Liu; Constantin Yiannoutsos; Jill Kolesar; Dorothea Horvath; Mary Jane Staab; Karen Fife; Victoria Armstrong; Anthony Treston; Carolyn Sidor; George Wilding Journal: Clin Cancer Res Date: 2005-09-15 Impact factor: 12.531
Authors: William L Dahut; Nehal J Lakhani; James L Gulley; Philip M Arlen; Elise C Kohn; Herbert Kotz; Debbie McNally; Allyson Parr; Diana Nguyen; Sherry X Yang; Seth M Steinberg; Jürgen Venitz; Alex Sparreboom; William D Figg Journal: Cancer Biol Ther Date: 2006-01-22 Impact factor: 4.742
Authors: Richard A Hughes; Trudi Harris; Emile Altmann; David McAllister; Ross Vlahos; Alan Robertson; Mark Cushman; Zhiqiang Wang; Alastair G Stewart Journal: Mol Pharmacol Date: 2002-05 Impact factor: 4.436
Authors: Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold Journal: J Clin Oncol Date: 2009-08-24 Impact factor: 44.544
Authors: I Duran; J Kortmansky; D Singh; H Hirte; W Kocha; G Goss; L Le; A Oza; T Nicklee; J Ho; D Birle; G R Pond; D Arboine; J Dancey; S Aviel-Ronen; M-S Tsao; D Hedley; L L Siu Journal: Br J Cancer Date: 2006-10-10 Impact factor: 7.640
Authors: Jennifer A Chan; Keith Stuart; Craig C Earle; Jeffrey W Clark; Pankaj Bhargava; Rebecca Miksad; Lawrence Blaszkowsky; Peter C Enzinger; Jeffrey A Meyerhardt; Hui Zheng; Charles S Fuchs; Matthew H Kulke Journal: J Clin Oncol Date: 2012-07-09 Impact factor: 44.544